跳轉至內容
Merck
全部照片(1)

Key Documents

Y0000700

峰鉴别用天然紫杉醇

European Pharmacopoeia (EP) Reference Standard

同義詞:

紫杉醇

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C47H51NO14
CAS號碼:
分子量::
853.91
Beilstein:
1420457
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

paclitaxel

製造商/商標名

EDQM

mp

213 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7

InChI

1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

InChI 密鑰

RCINICONZNJXQF-MZXODVADSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Paclitaxel natural for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

紫杉醇是一种有效的抗肿瘤和抗有丝分裂的紫杉烷类药物,可与 β-微管蛋白的N端结合,并使微管稳定,使细胞周期停滞在G2/M期。微管损伤通过依赖 JNK 的途径诱导细胞凋亡,随后通过不依赖 JNK 的途径诱导细胞凋亡,这可能与蛋白激酶 A(PKA)或 Raf-1 激酶的激活,进而导致 Bcl-2 磷酸化有关。通过 CYP2CB 的主要代谢物是 6α-羟基紫杉醇(6α-OHP)。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

注意

紫杉醇可在甲醇中进行酯交换反应,并在水溶液中发生水解。

其他說明

Sales restrictions may apply.

相關產品

產品號碼
描述
訂價

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Muta. 2 - Repr. 1B - STOT RE 1

標靶器官

Central nervous system,Bone marrow,Cardio-vascular system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Taroh Satoh et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(19), 2039-2049 (2014-05-29)
In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) -positive tumors. The role of anti-HER2 agents, including lapatinib, in this setting and population is unclear.
Erica Gornstein et al.
Neuropharmacology, 76 Pt A, 175-183 (2013-08-28)
Paclitaxel is a microtubule-binding compound that is widely used as a chemotherapeutic in the treatment of common cancers, including breast and ovarian cancer. Paclitaxel binding along the length of microtubules stabilizes them and suppresses their dynamics, leading to mitotic arrest
Zhiping Zhang et al.
Expert opinion on drug delivery, 10(3), 325-340 (2013-01-08)
Paclitaxel (PTX) is one of the most effective broad-spectrum chemotherapeutic agents in the treatment of cancers. However, its clinical application has been limited due to its poor water solubility. Its current clinical administration uses the adjuvant of serious side effects
Guido Bocci et al.
Angiogenesis, 16(3), 481-492 (2013-02-08)
In the mid 1990s, researchers began to investigate the antiangiogenic activity of paclitaxel as a possible additional mechanism contributing to its antineoplastic activity in vivo. In the last decade, a number of studies showed that paclitaxel has antiangiogenic activity that
Bradley J Monk et al.
The Lancet. Oncology, 15(8), 799-808 (2014-06-22)
Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to the Tie2 receptor, and thereby inhibits angiogenesis. We aimed to assess whether the addition of trebananib to single-agent

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務